Mucormycosis in ICU

NCT ID: NCT03387696

Last Updated: 2022-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-08

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.

ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU).

ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to :

* their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression
* the characteristics of the fungal infection
* the treatment strategy
* the severity of the initial illness, evaluated by severity scores

Twenty-one French ICU are currently including more than 45 patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucormycosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed or suspected mucormycosis, based on international definition from EORTC/MSG
* patient hospitalized in intensive care unit during the 2008-2016 period
* Zygomycosis identification in at least 2 solids organs or identification in hemoculture

Exclusion Criteria

* Age under 18 years old
* Patient under the law
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Intensive Care Unit - Hospital Amiens

Amiens, , France

Site Status

Intensive Care Unit - Hospital Angers

Angers, , France

Site Status

Intensive Care Unit - Hospital Besançon

Besançon, , France

Site Status

Intensive Care Unit - Hospital Béthune

Béthune, , France

Site Status

Intensive Care Unit - Hospital Caen

Caen, , France

Site Status

Intensive Care Unit - Hospital Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Intensive Care Unit - Hospital Dijon

Dijon, , France

Site Status

Intensive Care Unit - Hospital Grenoble Alpes

Grenoble, , France

Site Status

Intensive Care Unit - Hospital Lille

Lille, , France

Site Status

Intensive Care Unit - Hospital Lyon

Lyon, , France

Site Status

Intensive Care Unit - Hospital Montpellier

Montpellier, , France

Site Status

Intensive Care Unit - Hospital Nantes

Nantes, , France

Site Status

Intensive Care Unit - Hospital l'Archet - Nice

Nice, , France

Site Status

Intensive Care Unit - Hospital Bichat

Paris, , France

Site Status

Intensive Care Unit - Hospital Saint Louis

Paris, , France

Site Status

Intensive Care Unit - Hospital Tenon

Paris, , France

Site Status

Intensive Care Unit - Hospital Poitiers

Poitiers, , France

Site Status

Intensive Care Unit - Hospital Rennes

Rennes, , France

Site Status

Intensive Care Unit - Hospital Rouen

Rouen, , France

Site Status

Intensive Care Unit - Hospital Saint Etienne

Saint-Etienne, , France

Site Status

Intensive Care Unit - Hospital Tours

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZygoRea (38RC17.008)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Azole-resistance in Aspergillus
NCT03443336 COMPLETED
Dysbiosis & Long COVID
NCT06825819 RECRUITING